Literature DB >> 6419761

Oxazepam pharmacokinetics in thyroid disease.

A K Scott, A S Khir, P D Bewsher, G M Hawksworth.   

Abstract

The pharmacokinetics of oxazepam, a drug mainly eliminated by a single step glucuronidation reaction, were studied in seven hyperthyroid and six hypothyroid patients before and after treatment. Oxazepam elimination half-life was shorter and apparent oral clearance higher in untreated hyperthyroid patients than after treatment. There was no significant change in oxazepam elimination in hypothyroid subjects. Time to peak concentration (tmax) was reduced in the hyperthyroid state. Hypothyroidism had no significant effect on tmax. Serum bilirubin concentration was lower in the patients while hyperthyroid before treatment than when euthyroid and also lower than in the hypothyroid patients. There was no significant correlation between serum bilirubin concentrations and oxazepam elimination. These results suggest that glucuronyl transferase activity is increased in hyperthyroidism but is not altered in most patients with hypothyroidism. The extent of increase in glucuronyl transferase activity is similar to that produced by enzyme inducing drugs.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6419761      PMCID: PMC1463289          DOI: 10.1111/j.1365-2125.1984.tb04998.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  The kinetics of propylthiouracil in hyperthyroidism.

Authors:  J Kampmann; L Skovsted
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975-09

3.  Steatorrhea in thyrotoxicosis. Relation to hypermotility and excessive dietary fat.

Authors:  F B Thomas; J H Caldwell; N J Greenberger
Journal:  Ann Intern Med       Date:  1973-05       Impact factor: 25.391

4.  Proceedings: Changes in drug metabolizing ability in thyroid disease.

Authors:  J Crooks; A J Hedley; C Macnee; I H Stevenson
Journal:  Br J Pharmacol       Date:  1973-09       Impact factor: 8.739

5.  Unaltered metabolism of phenytoin in thyroid disorders.

Authors:  J Mølholm Hansen; L Skovsted; J P Kampmann; B I Lumholtz; K Siersbaek-Nielsen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1978-05

6.  Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction.

Authors:  E S Vesell; J R Shapiro; T Passananti; H Jorgensen; C A Shively
Journal:  Clin Pharmacol Ther       Date:  1975-01       Impact factor: 6.875

7.  Erythropoiesis and erythropoietin in hypo- and hyperthyroidism.

Authors:  K C Das; M Mukherjee; T K Sarkar; R J Dash; G K Rastogi
Journal:  J Clin Endocrinol Metab       Date:  1975-02       Impact factor: 5.958

8.  Oxazepam pharmacokinetics in patients with epilepsy treated long-term with phenytoin alone or in combination with phenobarbitone.

Authors:  A K Scott; A S Khir; W H Steele; G M Hawksworth; J C Petrie
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

9.  Paracetamol pharmacokinetics in thyroid disease.

Authors:  J C Forfar; A Pottage; A D Toft; W J Irvine; J A Clements; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

10.  Cimetidine spares the glucuronidation of lorazepam and oxazepam.

Authors:  R V Patwardhan; G W Yarborough; P V Desmond; R F Johnson; S Schenker; K V Speeg
Journal:  Gastroenterology       Date:  1980-11       Impact factor: 22.682

View more
  7 in total

1.  Does a selective 5-hydroxytryptamine antagonist (ICI 169, 369) lower blood pressure in hypertensive patients?

Authors:  A K Scott; P Roy-Chaudhury; J Webster; J C Petrie
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

2.  Interaction of metoprolol with lorazepam and bromazepam.

Authors:  A K Scott; G A Cameron; G M Hawksworth
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Proceedings of the British Pharmacological Society. Liverpool, 6th-8th April, 1988. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

Review 4.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

5.  Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism.

Authors:  J Sonne; S Boesgaard; H E Poulsen; S Loft; J M Hansen; M Døssing; F Andreasen
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

Review 6.  Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.

Authors:  H K Kroemer; U Klotz
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

7.  Kinetics of drug action in disease states. XXXI. Effect of experimental hyperthyroidism on the hypnotic activity of a benzodiazepine (oxazepam) in rats.

Authors:  J S Walker; P M Klockowski; G Levy
Journal:  Pharm Res       Date:  1989-05       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.